Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

April 30, 2012

Study Completion Date

July 31, 2020

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

Dendritic Cell Tumor Fusion

"Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.~Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT"

Trial Locations (4)

31096

Rambam Medical Center, Haifa

02114

Beth Israel Deaconess Medical Center, Boston

02115

Dana-Farber Cancer Institute/Brigham & Women's Hospital, Boston

02215

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Rambam Health Care Campus

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER

NCT00458653 - Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter